Compare Invesco DB Agriculture Fund (DBA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs BIO-TECHNE Corp — how do they compare? Invesco DB Agriculture Fund trades at $28.28 (market cap $1.32B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 8.6× Invesco DB Agriculture Fund's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and BIO-TECHNE Corp for 63 Days on average.
| DBA | TECH | |
|---|---|---|
Market Cap | $1.32B | $11.36B |
Volume | 771,657 | 5,390,331 |
52-Week High | $29.49 | $72.61 |
52-Week Low | $25.44 | $43.31 |
Typical Hold Time | 24 Days | 63 Days |
Sector | — | Health |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.295, down 0.68% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF has delivered strong 12.4% YTD returns, outperforming the S&P 500 in recent months according to Zacks Investment Research (2026-07-30). Recent news highlights agricultural ETF strength driven by weather risks and geopolitical tensions, though the fund carries a relatively high 0.85% expense ratio.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and global demand, but investors face volatility risks from commodity price swings and geopolitical uncertainty. Analyst sentiment remains mixed with Seeking Alpha maintaining a Hold rating (2026-09-22) while noting bullish long-term trends since 2020.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
